GILD vs LLY
GILD: A leading biopharmaceutical innovator specializing in life-saving HIV therapies and complex CAR T-cell cancer treatments. LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
Side-by-side fundamentals
| Metric | GILD | LLY | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $147.10 | $1,169.60 | |
| Market cap | $182.4B | $1.10T | |
| P/E as of 2026-10-08 | n/a | 39.25 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 0.80 | |
| Net margin FY2025, SEC XBRL | +28.9% | +31.7% | LLY higher |
| Operating margin FY2025, SEC XBRL | +34.0% | n/a | |
| ROE FY2025, SEC XBRL | +37.6% | +77.8% | LLY higher |
| ROA FY2025, SEC XBRL | +14.4% | +18.4% | LLY higher |
| Debt / equity as of 2026-09-03 | 2.22 | 1.62 | LLY lower |
| Revenue growth (YoY) as of 2026-09-03 | +5.5% | +49.6% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +2.6% | +31.7% | LLY higher |
| Dividend yield as of 2026-09-03 | +2.2% | +0.6% | GILD higher |
| Dividend streak (yrs) SEC XBRL | 11 | 10 | GILD higher |
| Beta as of 2026-09-03 | 0.37 | 0.55 | |
| 1-year return as of 2026-10-08 close | +24.4% | +38.3% | LLY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.